The role of stem cells in treating coronary artery disease in 2018

Research output: Contribution to journalReview article

Abstract

The last decade has witnessed the publication of a number of stem cell clinical trials, primarily using bone marrow-derived cells as the injected cell. Much has been learned through these “first-generation” clinical trials. The advances in our understanding include the following: (1) cell therapy is safe; (2) cell therapy has been mildly effective; and (3) human bone marrow-derived stem cells do not transdifferentiate into cardiomyocytes or new blood vessels. The primary mechanism of action for cell therapy is now believed to be through paracrine effects that include the release of cytokines, chemokines, and growth factors that inhibit apoptosis and fibrosis, enhance contractility, and activate endogenous regenerative mechanisms through endogenous circulating or site-specific stem cells. The current direction for clinical trials includes the use of stem cells capable of cardiac lineage.

Original languageEnglish (US)
Pages (from-to)340-348
Number of pages9
JournalIndian Journal of Thoracic and Cardiovascular Surgery
Volume34
DOIs
StatePublished - Dec 20 2018

Fingerprint

Coronary Artery Disease
Stem Cells
Cell- and Tissue-Based Therapy
Clinical Trials
Chemokines
Cardiac Myocytes
Bone Marrow Cells
Blood Vessels
Publications
Intercellular Signaling Peptides and Proteins
Fibrosis
Bone Marrow
Apoptosis
Cytokines

Keywords

  • Bone marrow mononuclear cells
  • Cardiac stem cells
  • Heart failure

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

The role of stem cells in treating coronary artery disease in 2018. / Michler, Robert E.

In: Indian Journal of Thoracic and Cardiovascular Surgery, Vol. 34, 20.12.2018, p. 340-348.

Research output: Contribution to journalReview article

@article{bcc49335aff4415aafa1129fd31bdc68,
title = "The role of stem cells in treating coronary artery disease in 2018",
abstract = "The last decade has witnessed the publication of a number of stem cell clinical trials, primarily using bone marrow-derived cells as the injected cell. Much has been learned through these “first-generation” clinical trials. The advances in our understanding include the following: (1) cell therapy is safe; (2) cell therapy has been mildly effective; and (3) human bone marrow-derived stem cells do not transdifferentiate into cardiomyocytes or new blood vessels. The primary mechanism of action for cell therapy is now believed to be through paracrine effects that include the release of cytokines, chemokines, and growth factors that inhibit apoptosis and fibrosis, enhance contractility, and activate endogenous regenerative mechanisms through endogenous circulating or site-specific stem cells. The current direction for clinical trials includes the use of stem cells capable of cardiac lineage.",
keywords = "Bone marrow mononuclear cells, Cardiac stem cells, Heart failure",
author = "Michler, {Robert E.}",
year = "2018",
month = "12",
day = "20",
doi = "10.1007/s12055-018-0739-7",
language = "English (US)",
volume = "34",
pages = "340--348",
journal = "Indian Journal of Thoracic and Cardiovascular Surgery",
issn = "0970-9134",
publisher = "Association of Thoracic and Cardiovascular Surgeons of India",

}

TY - JOUR

T1 - The role of stem cells in treating coronary artery disease in 2018

AU - Michler, Robert E.

PY - 2018/12/20

Y1 - 2018/12/20

N2 - The last decade has witnessed the publication of a number of stem cell clinical trials, primarily using bone marrow-derived cells as the injected cell. Much has been learned through these “first-generation” clinical trials. The advances in our understanding include the following: (1) cell therapy is safe; (2) cell therapy has been mildly effective; and (3) human bone marrow-derived stem cells do not transdifferentiate into cardiomyocytes or new blood vessels. The primary mechanism of action for cell therapy is now believed to be through paracrine effects that include the release of cytokines, chemokines, and growth factors that inhibit apoptosis and fibrosis, enhance contractility, and activate endogenous regenerative mechanisms through endogenous circulating or site-specific stem cells. The current direction for clinical trials includes the use of stem cells capable of cardiac lineage.

AB - The last decade has witnessed the publication of a number of stem cell clinical trials, primarily using bone marrow-derived cells as the injected cell. Much has been learned through these “first-generation” clinical trials. The advances in our understanding include the following: (1) cell therapy is safe; (2) cell therapy has been mildly effective; and (3) human bone marrow-derived stem cells do not transdifferentiate into cardiomyocytes or new blood vessels. The primary mechanism of action for cell therapy is now believed to be through paracrine effects that include the release of cytokines, chemokines, and growth factors that inhibit apoptosis and fibrosis, enhance contractility, and activate endogenous regenerative mechanisms through endogenous circulating or site-specific stem cells. The current direction for clinical trials includes the use of stem cells capable of cardiac lineage.

KW - Bone marrow mononuclear cells

KW - Cardiac stem cells

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=85059059870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059059870&partnerID=8YFLogxK

U2 - 10.1007/s12055-018-0739-7

DO - 10.1007/s12055-018-0739-7

M3 - Review article

VL - 34

SP - 340

EP - 348

JO - Indian Journal of Thoracic and Cardiovascular Surgery

JF - Indian Journal of Thoracic and Cardiovascular Surgery

SN - 0970-9134

ER -